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Despite the availability of 16 antiretroviral drugs approved for the treatment of HIV
infection, current combination regimens present challenges. Newer antiretroviral drugs
are needed to improve convenience, reduce toxicity and, of particular importance,
to provide antiretroviral activity against viral strains resistant to the currently avail-
able antiretroviral agents. Candidate drugs with novel properties are in development in
the two currently available drug classes: HIV reverse transcriptase inhibitors (nucleoside
analogs, non-nucleoside analogs and nucleotide analogs) and HIV protease inhibitors
(PI). Investigational nucleoside analog reverse transcriptase inhibitors (nRTI) include
emtricitabine (FTC) and amdoxovir (DAPD), and investigational non-nucleoside reverse
transcriptase inhibitors (NNRTI) include DPC 083 and TMC 125. New protease inhibitors
under investigation include atazanavir (BMS-232 632), tipranavir, and TMC 114. In
addition, newer agents with novel mechanisms of action such as HIV entry inhibitors
(that inhibit the three steps of HIV entry: CD4 attachment, chemokine receptor binding
and membrane fusion) and HIV integrase inhibitors are under investigation. Investiga-
tional entry inhibitors include PRO 542 (a CD4 attachment inhibitor), Schering C (a
chemokine receptor inhibitor), enfuvirtide (T-20) and T-1249, inhibitors of membrane
fusion. Investigational HIV integrase inhibitors include S-1360. Continued progress in the
treatment of HIV disease will result from the development of new antiretroviral drugs.
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INTRODUCTION
Currently, there are 16 antiretroviral drugs
approved for the treatment of HIV infection
[Table 1]. Treatment guidelines recommend con-
structing multidrug combinations of these agents
[1–4] and their widespread use has resulted in a
signiﬁcant decrease in HIV-related morbidity and
mortality in the developed world [5,6]. However,
current regimens continue to present challenges
with issues of adherence, tolerability, long-term
toxicity, and drug- and cross-resistance. Further
progress in treating HIV infection will result from
the development of antiretroviral drugs that are
convenient, tolerable, less toxic and demonstrate
activity against drug-resistant viruses. In addition
to improvements to the currently available anti-
retroviral drugs, investigational agents are in
development both in existing classes (reverse tran-
scriptase inhibitors, protease inhibitors) and in
new classes (entry inhibitors, integrase inhibitors)
[Table 2].
IMPROVEMENTS IN APPROVED
ANTIRETROVIRAL DRUGS
Currently available antiretroviral drugs have
improved over the last few years. New drug for-
mulations that allow once-daily dosing include an
approved enteric-coated formulation of didano-
sine and an extended release formulation of
stavudine. A sustained release formulation of
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zidovudine is also under investigation. Pharma-
cokinetic and clinical analyses have suggested
twice-daily dosing is appropriate for zidovudine,
zalcitabine, and nelﬁnavir, and once-daily dosing
is appropriate for lamivudine and possibly nevir-
apine. Exploiting the pharmacokinetic properties
of ritonavir, a potent inhibitor of the cytochrome
P450 3A4 hepatic enzyme system, allows com-
binations with other protease inhibitors (e.g.
saquinavir, indinavir, amprenavir, lopinavir) that
enhance drug levels, decrease pill counts, and
remove fasting requirements.
Fixed-dose multidrug formulations including
zidovudine/lamivudine, abacavir/zidovudine/
lamivudine and lopinavir/ritonavir reduce pill
counts and improve convenience. Improved dos-
ing formulations also are available for delavirdine
(200mg tablet) and efavirenz (600mg tablet) and
are under investigation for saquinavir (800mg
hard gel capsule) and nelﬁnavir (625mg tablet).
Finally, pro-drug formulations are under investi-
gation that reduce pill counts (e.g. GW433908, a
pro-drug of amprenavir) [7] or have potential to
increase lymphoid tissue penetration (e.g. GS 7340,
a pro-drug of tenofovir) [8]. Improved combina-
tion antiretroviral regimens will result from these
and other innovations.
NEW HIV REVERSE TRANSCRIPTASE
INHIBITORS
Emtricitabine (FTC) is an investigational analog of
the nucleoside, cytosine. The compound has activ-
ity against both hepatitis B virus [9] and HIV [10],
and it is incorporated ten-fold more efﬁciently
than lamivudine during HIV reverse transcription
[11]. Resistance to emtricitabine is conferred by
the M184V substitution in the reverse transcrip-
tase, a property shared with lamivudine [12]. The
pharmacokinetic proﬁle of emtricitabine supports
once-daily dosing [13] and the compound has been
studied as part of a once-daily regimen (combined
with didanosine and efavirenz) [14], with 93% of
subjects suppressing HIV RNA levels to <50
copies per ml (cpm) by 24weeks and continued
suppression through 96weeks [15]. Emtricitabine
also was investigated in a study where subjects
on a stable regimen substituted emtricitabine for
lamivudine, and virologic suppression was main-
tained [16]. In a study of treatment-naı¨ve subjects
in South Africa randomized to receive stavudine
and nevirapine (or efavirenz) together with either
Table 1 Currently approved antiretroviral drugs
HIV reverse transcriptase inhibitors
Nucleoside analogs
zidovudine (ZDV, AZT)
didanosine (ddI)
zalcitabine (ddC)
stavudine (d4T)
lamivudine (3TC)
abacavir (ABC)
Non-nucleoside analogs (NNRTI)
nevirapine (NVP)
delavirdine (DLV)
efavirenz (EFV)
Nucleotide analogs
tenofovir (TDF)
HIV protease inhibitors
saquinavir (SQV)
ritonavir (RTV)
indinavir (IDV)
nelfinavir (NFV)
amprenavir (APV)
lopinavir/ritonavir (LPV/r)
Table 2 Investigational antiretroviral drugs (partial list)
HIV reverse transcriptase inhibitors
Nucleoside analogs
emtricitabine (FTC)
amdoxovir (DAPD)
Non-nucleoside analogs
DPC-083
capravirine (Ag 1549)
TMC 125
calanolide A
Nucleotide analogs
GS-7340 (tenofovir pro-drug)
HIV protease inhibitors
atazanavir (ATV, BMS-232 632)
tipranavir (TPV, PNU-140690)
mozenavir (DMP-450)
TMC 114
HIV entry inhibitors
CD4 attachment inhibitors
PRO 542
BMS-806
Chemokine receptor inhibitors – CXCR4
AMD-3100
Chemokine receptor inhibitors – CCR5
Schering C (SCH-C, SCH 351125)
PRO 140
Schering D (SCH-D)
UK 427,857
Fusion inhibitors
enfuvirtide (T-20)
T-1249
HIV integrase inhibitors
S-1360
development discontinued
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emtricitabine or lamivudine, ﬁve deaths due to
hepatic failure thought related to nevirapine
occurred [17].
Amdoxovir (DAPD, diaminopurine dioxolane)
is an investigational analog of the nucleoside gua-
nosine that is deaminated in vivo to DXG (dioxo-
lane guanine), the active compound with activity
against both HIV and HBV [18]. In vitro, the com-
pound demonstrates activity against some nucleo-
side-resistance viruses, including those with the 69
insertion (that confers multinucleoside resistance)
[19]. However, reverse transcriptase substitutions
at K65R or L74V reduce susceptibility to amdox-
ovir. Animal toxicity studies demonstrated ob-
structive nephropathy (due to crystallization of
the drug in the renal tubules) leading to hyper-
glycemia and cataracts in some animals. A clinical
study in treatment-naı¨ve and treatment-experi-
enced subjects demonstrated potent antiretroviral
activity (HIV RNA changes of 1.5 log10 cpm in
treatment-naı¨ve and1.1 log10 cpm in nucleoside-
experienced subjects over 14 days) [20,21]. Further
studies are in progress.
DPC 083 is an investigational quinazolinone
NNRTI that is a derivative of efavirenz. In vitro,
the compound has increased activity against HIV
with reverse transcriptase substitutions at posi-
tions K103N, K101E and G190S, and resistance
to DPC 083 requires more than one substitution
(in contrast to currently available NNRTIs) [22,23].
The half-life of the compound is>90 h, supporting
once-daily (or perhaps less frequent) dosing [23].
Recent phase II studies demonstrate the antiretro-
viral activity of the compound in both treatment-
naı¨ve and NNRTI-experienced subjects. In one
study, treatment-naı¨ve individuals received zido-
vudine/lamivudine in combinationwith 50, 100 or
200mg of DPC 083 or efavirenz [24]. Virologic
response rates were similar at week 16 for all of
the combination regimens with about 60–70% of
subjects with HIV RNA levels of <50 cpm. In a
study of NNRTI-experienced subjects, subjects
received two nucleoside analogs in combination
with DPC 083 100mg or 200mg once daily [25]. At
16weeks, about 40–50% of subjects had HIV RNA
levels of <400 cpm, suggesting the activity of DPC
083 against viral variants with resistance to cur-
rently available NNRTI.
TMC 125 is an investigational NNRTI with
potent antiretroviral activity in vitro against
viruses resistant to currently available NNRTI,
and that requires at least two substitutions in
the reverse transcriptase gene for resistance to
develop [26]. In a pilot study in treatment-naı¨ve
subjects, TMC 125 900mg bid monotherapy was
associated with a2.0 log10 cpmHIV RNA change
from baseline over 7 days [27]. In another pilot
study of NNRTI-experienced subjects, TMC 125
was associated with about a 1 log10 cpm HIV
RNA change over 7 days [28]. Longer-term studies
are in progress.
HIV PROTEASE INHIBITORS
Atazanavir (BMS-232 632) is an investigational
protease inhibitor (PI) with in vitro activity against
wild-type virus and some viral variants with PI-
associated mutations [29,30]. However, in a pedia-
tric study, cross-resistance among protease inhi-
bitors occurred in heavily pretreated subjects [31].
Pharmacokinetics support once-daily dosing [32].
Large phase III studies were reported recently. In
one study, treatment-naı¨ve subjects received sta-
vudine/lamivudine with either atazanavir (400 or
600mg qd) or nelﬁnavir 1250mg bid [33]. At
24weeks, 60–70% of the subjects had HIV RNA
levels of <400 cpm. In another study, treatment-
experienced subjects received two nucleoside ana-
logs with either atazanavir (400 or 600mg)/saqui-
navir (1200mg) qd or ritonavir (400mg)/
saquinavir (400mg) bid [34]. Overall at 48weeks,
HIV RNA change from baseline was1.2–1.7 log10
cpm. In both of these studies, serum lipid levels
increased in the comparator arms, but not with the
atazanavir regimens [34,35]. An expanded access
program for atazanavir is now available.
Tipranavir (PNU-140690) is a nonpeptidic
investigational PI with potent HIV activity in vitro
[36] with drug levels increased markedly by coad-
ministration with ritonavir [37]. A new self-emul-
sifying drug delivery system (SEDDS) formulation
of the drug is under investigation. Tipranavir
demonstrated antiretroviral activity in vitro
against viral isolates with phenotypic resistance
to currently available PIs [38]. In one study, single-
PI-experienced subjects were randomized to
receive two nucleoside analogs with tipranavir
(500 or 1250mg)/ritonavir (100mg) or saquinavir
(400mg)/ritonavir (400mg) given twice daily [39].
At 16weeks, medianHIV RNA changes from base-
line were1.4–1.8 log10 cpm. In a study of patients
experiencing virologic failure on their second PI
regimen, subjects were randomized to receive
tipranavir (500 or 1000mg)/ritonavir (100mg)
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twice daily [40]. At 48weeks in the lower-dose
group, the mean change in HIV RNA was 2.4
log10 cpm for subjects with 5 PI-associated resis-
tance mutations vs. 2.2 log10 cpm with >5 muta-
tions. Further studies in both treatment-naı¨ve and
treatment-experienced patients are in progress.
TMC 114, an analog of TMC 126, a ‘resistance-
repellant’ PI [41], is an investigational nonpeptidic
PI with in vitro activity against viral isolates, some
of which had high-level resistance to currently
available PIs [42]. The ﬁrst study of TMC 114
was conducted in healthy volunteers who received
escalating single doses of the drug (100–4000mg)
[43]. For doses of 800mg and higher, plasma levels
exceeded the protein-adjusted 50% inhibitory con-
centration for some PI-resistant viral isolates. Stu-
dies in HIV-infected subjects are in progress.
HIV ENTRY INHIBITORS
HIV entry, the ﬁrst step in the viral life cycle, is
composed of three steps: (1) CD4 cell receptor
binding; (2) chemokine receptor (CCR5 or CXCR4)
binding; and (3) membrane fusion. HIV entry
inhibitors target each of these steps: CD4 attach-
ment inhibitors; chemokine receptor inhibitors,
and fusion inhibitors.
PRO 542, an investigational CD4 attachment
inhibitor, is an antibody-like fusion protein of
CD4 and IgG2. The compound binds HIV gp120
and showed activity against primary viral isolates
in vitro [44], and in animal models [45]. In a single-
dose phase I study, HIV-infected adults received
one intravenous infusion of PRO 542 at doses of
0.2, 1, 5 or 10mg/kganddose-dependentHIVRNA
decreases were observed [46]. In another study of
single and multiple intravenous doses of PRO 542
in 18 HIV-infected children, subjects received
four-weekly 10mg/kg doses of PRO 542 and four
of six demonstrated HIV RNA decreases of > 0.7
log10 cpm [47]. Further studies are in progress.
Schering C (SCH 351125, SCH-C) is an investi-
gational orally bioavailable chemokine receptor
(CCR5) inhibitor with potent antiretroviral activity
and pharmacokinetics to support twice-daily dos-
ing [48]. In vitro, the development of resistance to
SCH-C was not accompanied by receptor switch-
ing (from CCR5 to CXCR4) [49]. The ﬁrst study of
the compound in healthy volunteers assessed sin-
gle doses of up to 600mg and 14days of dosing
with 400mg, and demonstrated QTc interval
prolongation at the highest doses tested in both
studies [50]. In a pilot study of HIV-infected
patients, subjects received SCH-C 25mg every
12 h and the median HIV RNA decrease from
baseline was – 0.7 log10 cpm at 10 days [51].
Further testing at higher doses is in progress.
Enfuvirtide (T-20) is an investigational peptide
inhibitor of HIV fusion that must be given par-
enterally. The compound binds to a portion of the
HIV gp41 molecule and thereby inhibits fusion of
the viral and cell membranes [52]. The ﬁrst study
of enfuvirtide in HIV-infected subjects demon-
strated up to a median 2.0 log10 cpm change in
HIV RNA levels over 14 days [53]. In some subjects
randomized to lower doses with partial virologic
suppression, drug resistance associated with sub-
stitutions in envelope protein genes was observed
[54]. A phase II study of heavily treatment-experi-
enced subjects tested antiretroviral regimens
selected with genotypic testing plus the addition
of T-20 50mg bid, and demonstrated signiﬁcant
virologic activity in a substantial proportion of
subjects [55]. In another study, PI-experienced
subjects were randomized to abacavir, amprena-
vir, ritonavir and efavirenz  T-20 (50, 75, or
100mg bid) for 48weeks and demonstrated better
virologic suppression in the T-20 groups (2.1–2.6
log10 cpm HIV RNA change) than in the control
group (1.9 log10 cpm HIV RNA change) [56].
Results from two phase III studies were released
recently, demonstrating the additional virologic
beneﬁts of using T-20 as part of a regimen for
treatment-experienced subjects and complete
results are anticipated [57, 58].
T-1249 is a second investigational HIV fusion
inhibitor that is two to 100-fold more active than
T-20 in vitro, with pharmacokinetics to support
once- or twice-daily dosing. The ﬁrst study in HIV-
infected, treatment-experienced subjects tested
T-1249 as a single agent at escalating subcutaneous
doses ranging from 6.25mg to 50mg [59]. HIV
RNA changes of up to 1.4 log10 cpm were de-
monstrated at the highest dose tested and pre-
existing resistance to reverse transcriptase andpro-
tease inhibitors did not impact virologic response
[60].
HIV INTEGRASE INHIBITORS
HIV integration is catalyzed by the viral enzyme
HIV integrase and consists of three steps: (1) viral
DNA complex assembly; (2) viral DNA complex
processing; and (3) strand transfer linking viral
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and cellular DNA and a number of inhibitors have
been identiﬁed [61]. The ﬁrst to reach clinical
studies is S-1360, an investigational integrase inhi-
bitor that showed potent antiretroviral activity
in vitro and in an animal model [60]. S-1360
selected resistance mutants with amino acid sub-
stitutions close to the active site of integrase in
vitro. The drug is orally bioavailable and phase
I/II studies with HIV-infected subjects are under-
way.
CONCLUSIONS
Despite dramatic improvements in the morbidity
and mortality of HIV-infected patients directly
resulting from antiretroviral therapy, better anti-
retroviral drugs are needed. In addition to innova-
tions that continue to improve the currently
available antiretroviral drugs, a number of promis-
ing compounds are under investigation. Newer
agents in existing classes (reverse transcriptase
and protease inhibitors) and newer mechanistic
classes (entry inhibitors, integrase inhibitors) have
the potential to improve convenience, reduce toxi-
city and enhance activity against drug-resistant
virus. Further basic and clinical research is neces-
sary.
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